10-Q Filing

Processa Pharmaceuticals, Inc. CIK: 1533743 Q2 2019

Filing Information

Form Type	10-Q
Accession Number	`0001493152-19-012368`
Period End Date	20190630
Filing Date	20190814
Fiscal Year	2019
Fiscal Period	Q2
XBRL Instance	pcsa-20190630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 84 Income Statement 50 Cash Flow Statement 82 Stockholders Equity 30

Balance Sheet 84 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$721.99K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.74M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	$21.58K	USD	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	-	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$257.83K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$267.92K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$2.02M	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$989.91K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	38.67M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	38.67M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	38.67M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	38.67M	shares	Point-in-time
Software	`CapitalizedComputerSoftwareGross`	$19.74K	USD	Point-in-time
Software	`CapitalizedComputerSoftwareGross`	$19.74K	USD	Point-in-time
Office equipment	`MachineryAndEquipmentGross`	$9.33K	USD	Point-in-time
Office equipment	`MachineryAndEquipmentGross`	$9.33K	USD	Point-in-time
Total Cost	`PropertyPlantAndEquipmentGross`	$29.07K	USD	Point-in-time
Total Cost	`PropertyPlantAndEquipmentGross`	$29.07K	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$11.69K	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$15.91K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$17.38K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$13.15K	USD	Point-in-time
Operating lease right of use assets, net of accumulated amortization	`OperatingLeaseRightOfUseAsset`	$256.92K	USD	Point-in-time
Operating lease right of use assets, net of accumulated amortization	`OperatingLeaseRightOfUseAsset`	$293.20K	USD	Point-in-time
Intangible assets, net of accumulated amortization	`IntangibleAssetsNetExcludingGoodwill`	$10.04M	USD	Point-in-time
Intangible assets, net of accumulated amortization	`IntangibleAssetsNetExcludingGoodwill`	$10.44M	USD	Point-in-time
Security deposit	`SecurityDeposit`	$5.54K	USD	Point-in-time
Security deposit	`SecurityDeposit`	$5.54K	USD	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$10.44M	USD	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$10.30M	USD	Point-in-time
Total Assets	`Assets`	$11.31M	USD	Point-in-time
Total Assets	`Assets`	$12.48M	USD	Point-in-time
Senior convertible notes	`SeniorNotesCurrent`	$230.00K	USD	Point-in-time
Senior convertible notes	`SeniorNotesCurrent`	$230.00K	USD	Point-in-time
Current maturities of operating lease liability	`OperatingLeaseLiabilityCurrent`	$77.54K	USD	Point-in-time
Current maturities of operating lease liability	`OperatingLeaseLiabilityCurrent`	-	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$28.93K	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$20.34K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$143.35K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$292.10K	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	-	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	$1.34K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$103.26K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$302.27K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$645.70K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$783.44K	USD	Point-in-time
Noncurrent operating lease liability	`OperatingLeaseLiabilityNoncurrent`	-	USD	Point-in-time
Noncurrent operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$186.68K	USD	Point-in-time
Net deferred tax liability	`DeferredTaxLiabilitiesNoncurrent`	$2.13M	USD	Point-in-time
Net deferred tax liability	`DeferredTaxLiabilitiesNoncurrent`	$1.83M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.78M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.80M	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value $0.0001, 10,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.0001, 10,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.0001, 350,000,000 shares authorized; 38,674,265 issued and outstanding at both June 30, 2019 and December 31, 2018	`CommonStockValue`	$3.87K	USD	Point-in-time
Common stock, par value $0.0001, 350,000,000 shares authorized; 38,674,265 issued and outstanding at both June 30, 2019 and December 31, 2018	`CommonStockValue`	$3.87K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$19.25M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$19.12M	USD	Point-in-time
Subscription receivable	`CommonStockSharesSubscriptions`	$1.40M	USD	Point-in-time
Subscription receivable	`CommonStockSharesSubscriptions`	$1.80M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-9.34M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-7.62M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$11.31M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$8.50M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$9.70M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$373.16K	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$9.12M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$7.28M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$12.48M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$11.31M	USD	Point-in-time

Income Statement 50 line items

Line Item	Tag	Value	Unit	Period
Research and development expenses	`ResearchAndDevelopmentExpense`	$1.21M	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$1.87M	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$726.90K	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpense`	$1.08M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$853.92K	USD	2 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$350.58K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$410.07K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$807.84K	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$2.02M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$1.43M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$2.72M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$1.14M	USD	1 Quarter
Operating Loss	`OperatingIncomeLoss`	$-2.72M	USD	2 Qtrs
Operating Loss	`OperatingIncomeLoss`	$-1.43M	USD	1 Quarter
Operating Loss	`OperatingIncomeLoss`	$-2.02M	USD	2 Qtrs
Operating Loss	`OperatingIncomeLoss`	$-1.14M	USD	1 Quarter
Interest expense	`InterestExpense`	$146.05K	USD	2 Qtrs
Interest expense	`InterestExpense`	$58.31K	USD	1 Quarter
Interest expense	`InterestExpense`	$10.70K	USD	2 Qtrs
Interest expense	`InterestExpense`	$6.10K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$3.71K	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$3.40K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$2.68K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$9.38K	USD	2 Qtrs
Total other income (expense)	`OtherOperatingIncomeExpenseNet`	$-1.32K	USD	2 Qtrs
Total other income (expense)	`OtherOperatingIncomeExpenseNet`	$-2.70K	USD	1 Quarter
Total other income (expense)	`OtherOperatingIncomeExpenseNet`	$-55.63K	USD	1 Quarter
Total other income (expense)	`OtherOperatingIncomeExpenseNet`	$-142.35K	USD	2 Qtrs
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-2.02M	USD	2 Qtrs
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-2.86M	USD	2 Qtrs
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.14M	USD	1 Quarter
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.48M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-170.60K	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-300.90K	USD	2 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	$-277.78K	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-559.32K	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-1.21M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-750.83K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-1.10M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-1.72M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-969.08K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-2.30M	USD	2 Qtrs
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.03	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.04	USD	2 Qtrs
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.03	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.06	USD	2 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	38.67M	shares	1 Quarter
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	35.95M	shares	2 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	38.67M	shares	2 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	36.62M	shares	1 Quarter

Cash Flow Statement 82 line items

Line Item	Tag	Value	Unit	Period
Common stock, shares transferred	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	2.09M	shares	2 Qtrs
Common stock, shares transferred	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	2.09M	shares	1 Quarter
Conversion of senior convertible debt, value	`ConversionOfSeniorConvertibleDebtValue`	$2.35M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-1.21M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-750.83K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-1.10M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-1.72M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-969.08K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-2.30M	USD	2 Qtrs
Accrued interest converted into shares of common stock and warrants	`AccruedInterestConvertedIntoSharesOfCommonStockAndWarrants`	1.21M	shares	2 Qtrs
Depreciation	`Depreciation`	$4.22K	USD	2 Qtrs
Depreciation	`Depreciation`	$4.22K	USD	2 Qtrs
Amortization of right-of-use assets	`AmortizationOfRightofuseAssets`	-	USD	2 Qtrs
Amortization of right-of-use assets	`AmortizationOfRightofuseAssets`	$36.28K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	-	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	$61.13K	USD	2 Qtrs
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$222.56K	USD	2 Qtrs
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$397.66K	USD	2 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-559.32K	USD	2 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-300.90K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$125.03K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	-	USD	2 Qtrs
Payments made directly to our Contract Research Organization for clinical trial expenses by an investor in partial satisfaction of their stock subscription receivable	`PaymentsMadeDirectlyToOurContractResearchOrganizationForClinicalTrialExpensesByInvestorInPartialSatisfactionOfTheirStockSubscriptionReceivable`	$395.93K	USD	2 Qtrs
Payments made directly to our Contract Research Organization for clinical trial expenses by an investor in partial satisfaction of their stock subscription receivable	`PaymentsMadeDirectlyToOurContractResearchOrganizationForClinicalTrialExpensesByInvestorInPartialSatisfactionOfTheirStockSubscriptionReceivable`	-	USD	2 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$10.09K	USD	2 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$42.07K	USD	2 Qtrs
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	-	USD	2 Qtrs
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$38.94K	USD	2 Qtrs
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$8.59K	USD	2 Qtrs
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$84.72K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-148.75K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$200.71K	USD	2 Qtrs
Due (from)/to related parties	`IncreaseDecreaseInDueToRelatedParties`	$22.92K	USD	2 Qtrs
Due (from)/to related parties	`IncreaseDecreaseInDueToRelatedParties`	$6.88K	USD	2 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$208.98K	USD	2 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$90.84K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.02M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.23M	USD	2 Qtrs
Purchase of intangible asset	`PaymentsToAcquireIntangibleAssets`	$1.78K	USD	2 Qtrs
Purchase of intangible asset	`PaymentsToAcquireIntangibleAssets`	-	USD	2 Qtrs
Proceeds from (purchase of) certificates of deposit	`PaymentsToAcquireRestrictedCertificatesOfDeposit`	-	USD	2 Qtrs
Proceeds from (purchase of) certificates of deposit	`PaymentsToAcquireRestrictedCertificatesOfDeposit`	$496.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-497.78K	USD	2 Qtrs
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$2.86M	USD	2 Qtrs
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	2 Qtrs
Transaction costs incurred on Senior Convertible Notes	`ProceedsFromUnsecuredNotesPayable`	-	USD	2 Qtrs
Transaction costs incurred on Senior Convertible Notes	`ProceedsFromUnsecuredNotesPayable`	$4.74K	USD	2 Qtrs
Payment of placement agent and legal fees associated with clinical funding commitment	`ProceedsFromPaymentsForOtherFinancingActivities`	$-117.34K	USD	2 Qtrs
Payment of placement agent and legal fees associated with clinical funding commitment	`ProceedsFromPaymentsForOtherFinancingActivities`	-	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.73M	USD	2 Qtrs
Net (Decrease)/Increase in Cash and Cash Equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$3.02K	USD	2 Qtrs
Net (Decrease)/Increase in Cash and Cash Equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.02M	USD	2 Qtrs
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.85M	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.74M	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.85M	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$721.99K	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.85M	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.74M	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.85M	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$721.99K	USD	Point-in-time
Right-of-use asset obtained in exchange for operating lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$293.20K	USD	2 Qtrs
Right-of-use asset obtained in exchange for operating lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	-	USD	2 Qtrs
Reduction in deferred lease liability	`ReductionInDeferredLeaseLiability`	$-9.96K	USD	2 Qtrs
Reduction in deferred lease liability	`ReductionInDeferredLeaseLiability`	-	USD	2 Qtrs
Operating lease liability	`OperatingLeaseLiabilities`	$303.16K	USD	2 Qtrs
Operating lease liability	`OperatingLeaseLiabilities`	-	USD	2 Qtrs
Recognize the exclusive license intangible asset acquired from CoNCERT	`RecognizeExclusiveLicenseIntangibleAssetAcquired`	$-11.04M	USD	2 Qtrs
Recognize the exclusive license intangible asset acquired from CoNCERT	`RecognizeExclusiveLicenseIntangibleAssetAcquired`	-	USD	2 Qtrs
Recognize deferred tax liability for basis difference for Intangible asset	`RecognizationOfDeferredTaxLiability`	$3.04M	USD	2 Qtrs
Recognize deferred tax liability for basis difference for Intangible asset	`RecognizationOfDeferredTaxLiability`	-	USD	2 Qtrs
Recognize additional paid-in capital for consideration paid from the transfer of 2,090,301 common shares of Processa released by Promet to CoNCERT for Processa	`PaymentOfAdditionalPaidInCapitalForConsideration`	-	USD	2 Qtrs
Recognize additional paid-in capital for consideration paid from the transfer of 2,090,301 common shares of Processa released by Promet to CoNCERT for Processa	`PaymentOfAdditionalPaidInCapitalForConsideration`	$8.00M	USD	2 Qtrs
Net	`NonCashInvestingAndFinancingActivitiesNet`	-	USD	2 Qtrs
Net	`NonCashInvestingAndFinancingActivitiesNet`	-	USD	2 Qtrs
Conversion of $2,350,000 of Senior Convertible Debt and related accrued interest into 1,206,245 shares of common stock and warrants	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStockAndWarrants`	$2.40M	USD	2 Qtrs
Conversion of $2,350,000 of Senior Convertible Debt and related accrued interest into 1,206,245 shares of common stock and warrants	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStockAndWarrants`	-	USD	2 Qtrs
Common stock and stock purchase warrants issued in connection with a clinical trial funding commitment	`CommonStockAndStockPurchaseWarrantsIssuedInConnectionWithClinicalTrialFundingCommitment`	-	USD	2 Qtrs
Common stock and stock purchase warrants issued in connection with a clinical trial funding commitment	`CommonStockAndStockPurchaseWarrantsIssuedInConnectionWithClinicalTrialFundingCommitment`	$1.80M	USD	2 Qtrs
Note receivable related to the sale of common stock and stock purchase warrants	`NoteReceivableRelatedToSaleOfCommonStockAndStockPurchaseWarrants`	$107.49K	USD	2 Qtrs
Note receivable related to the sale of common stock and stock purchase warrants	`NoteReceivableRelatedToSaleOfCommonStockAndStockPurchaseWarrants`	-	USD	2 Qtrs

Stockholders Equity 30 line items

Line Item	Tag	Value	Unit	Period
Conversion of stock, costs	`ConversionOfStockNetOfCosts`	$4.74K	USD	1 Quarter
Issuance of common stock units for cash, cost	`PaymentsOfStockIssuanceCosts`	$219.95K	USD	1 Quarter
Issuance of common stock units for a future research funding commitment, cost	`IssuanceOfCommonStockUnitsForFutureResearchFundingCommitmentCost`	$117.34K	USD	1 Quarter
Balance	`StockholdersEquity`	$11.31M	USD	Point-in-time
Balance	`StockholdersEquity`	$8.50M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.70M	USD	Point-in-time
Balance	`StockholdersEquity`	$373.16K	USD	Point-in-time
Balance	`StockholdersEquity`	$9.12M	USD	Point-in-time
Balance	`StockholdersEquity`	$7.28M	USD	Point-in-time
Recognize the fair value of exclusive license intangible asset acquired from CoNCERT in exchange for 2,090,301 commonshares of Processa held by Promet	`AdjustmentsToAdditionalPaidInCapitalOther`	$8.00M	USD	1 Quarter
Conversion of Senior convertible notes for common stock and stock purchase warrants, net of costs of $4,742	`StockIssuedDuringPeriodValueConversionOfUnits`	$2.39M	USD	1 Quarter
Issuance of common stock units for cash, net of costs of $219,954	`StockIssuedDuringPeriodValueNewIssues`	$2.96M	USD	1 Quarter
Issuance of common stock units for a future research funding commitment, net of costs of $117,339	`StockIssuedDuringPeriodValueOther`	$-117.34K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$58.56K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$66.48K	USD	1 Quarter
Payments made directly by investor for clinical trial costs	`PaymentsMadeDirectlyByInvestorForClinicalTrialCosts`	$280.93K	USD	1 Quarter
Payments made directly by investor for clinical trial costs	`PaymentsMadeDirectlyByInvestorForClinicalTrialCosts`	$115.00K	USD	1 Quarter
Payments made directly by investor for clinical trial costs	`PaymentsMadeDirectlyByInvestorForClinicalTrialCosts`	$395.93K	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-1.21M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-750.83K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.10M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.72M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-969.08K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.30M	USD	2 Qtrs
Balance	`StockholdersEquity`	$11.31M	USD	Point-in-time
Balance	`StockholdersEquity`	$8.50M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.70M	USD	Point-in-time
Balance	`StockholdersEquity`	$373.16K	USD	Point-in-time
Balance	`StockholdersEquity`	$9.12M	USD	Point-in-time
Balance	`StockholdersEquity`	$7.28M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.